BCS1L as a Potential Drug Target and Biomarker for Mitochondrial Complex III Assembly

Target Name: BCS1L

NCBI ID: G617

BCS1L

BCS1L as a Potential Drug Target and Biomarker for Mitochondrial Complex III Assembly

Introduction

Mitochondrial Complex III (MCO III) is a protein complex that plays a crucial role in the production of ATP, a vital energy source for the cell. MCO III is composed of four subunits: MCO III alpha, MCO III beta, MCO III gamma, and MCO III delta. The MCO III complex is responsible for creating the proton gradient that is essential for the production of ATP through the electron transport chain. MCO III assembly is a highly regulated process that involves multiple interactions between its subunits.

The BCS1L gene, which encodes the protein BCS1L (Biochimica et Servilletin-like), is a key regulator of MCO III assembly. BCS1L functions by forming a complex with the MCO III subunit alpha (MCO III alpha) and helps to maintain the stability of the MCO III complex. MCO III alpha is the largest subunit of MCO III and plays a critical role in regulating the assembly and disassembly of MCO III.

BSC1L function in MCO III assembly has been studied extensively, and several studies have identified potential drug targets and biomarkers associated with MCO III assembly. In this article, we will review the current understanding of BCS1L function in MCO III assembly and discuss its potential as a drug target and biomarker.

BCS1L-MCO III Complex

The BCS1L gene encodes a protein that contains multiple domains, including a N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T-loop domain. The N-terminal transmembrane domain is responsible for the formation of the BCS1L- MCO III complex.

The BCS1L-MCO III complex is formed when BCS1L binds to MCO III alpha. The binding is reversible and can be characterized by the presence of a N-terminal translocation domain in BCS1L, which is responsible for the exchange of genetic information between BCS1L and MCO III alpha. The coiled-coil domain in BCS1L is involved in the formation of the N-terminal translocation domain.

The MCO III alpha subunit is the largest subunit of MCO III and plays a critical role in regulating the assembly and disassembly of MCO III. MCO III alpha contains two unique domains: a N-terminal alpha-helices domain and a C-terminal alpha- helix domain. The N-terminal alpha-helices domain is involved in the regulation of MCO III alpha stability and plays a role in the formation of the MCO III alpha-BCS1L interaction. The C-terminal alpha-helices domain is involved in the regulation of MCO III alpha stability and plays a role in the formation of the MCO III alpha-BCS1L interaction.

BSC1L-MCO III Interaction

The BCS1L-MCO III interaction is regulated by multiple factors, including the concentration of MCO III alpha, the pH of the environment, and the presence of other proteins that can modulate the activity of BCS1L. The interaction between BCS1L and MCO III alpha is characterized by a high degree of binding affinity, with a KD value of approximately 20 nM.

The binding between BCS1L and MCO III alpha is reversible and can be characterized by the presence of a N-terminal translocation domain in BCS1L. The N-terminal translocation domain is responsible for the exchange of genetic information between BCS1L and MCO III alpha. The translation of the N-terminal translocation domain is regulated by multiple factors, including the concentration of MCO III alpha, the pH of the environment, and the presence of other proteins that can modulate the activity of

Protein Name: BCS1 Homolog, Ubiquinol-cytochrome C Reductase Complex Chaperone

Functions: Chaperone necessary for the assembly of mitochondrial respiratory chain complex III. Plays an important role in the maintenance of mitochondrial tubular networks, respiratory chain assembly and formation of the LETM1 complex

The "BCS1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCS1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets